IDEXX Laboratories, Inc. ( IDXX ) NASDAQ Global Select

Cena: 565.19 ( 2.77% )

Aktualizacja 07-25 22:00
NASDAQ Global Select
Branża: Medical - Diagnostics & Research
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Opis firmy:

IDEXX Laboratories, Inc. opracowuje, produkuje i dystrybuuje produkty i usługi przede wszystkim na rynki towarzyszące zwierząt weterynaryjnych, zwierząt gospodarskich i drobiu, nabiału i testowania wody na całym świecie. Firma działa za pośrednictwem CAG; Produkty jakości wody; LPD; i inne segmenty. Zapewnia produkty diagnostyczne weterynaryjne w zakresie opieki, w tym instrumenty, materiały eksploatacyjne i zestawy testowe szybkiego testu; weterynaryjne usługi diagnostyczne i konsultacyjne laboratoryjne; praktyka zarządzania i diagnostyczne systemy i usługi obrazowania dla lekarzy weterynarii; oraz monitorowanie zdrowia, testowanie materiałów biologicznych oraz laboratoryjne instrumenty diagnostyczne zwierząt i usługi dla społeczności badawczej. Firma oferuje również produkty diagnostyczne i monitorujące zdrowie dla zwierząt gospodarskich, drobiu i nabiału; produkty, które testują wodę dla różnych zanieczyszczeń mikrobiologicznych; oraz elektrolity i analizatory gazów krwi oraz SARS-COV-2 RT-PCR, które są stosowane na rynku diagnostyki medycznej ludzkiej opieki; Chemia w klinicznej, chemia krwi i moczu, hematologia i analizy DX uszywczy; Zestawy testowe Snap Szybkie testy. Ponadto zapewnia testy colilert, colilert-18 i kolisury, które wykrywają obecność całkowitej grupy coli i E. coli w wodzie; Enterolelert, Pseudalelert, Filta-Max i Filta-Max Xpress, Legioolert i Quanti Tayt; Oprogramowanie weterynaryjne i usługi dla niezależnych klinik weterynaryjnych i grup korporacyjnych. Firma sprzedaje swoje produkty poprzez marketing, obsługę klienta, sprzedaż i techniczne grupy usług, a także poprzez niezależnych dystrybutorów i innych sprzedawców. Idexx Laboratories, Inc. został włączony w 1983 roku i ma siedzibę w Westbrook, Maine.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Diagnostics & Research
Zatrudnienie: 11 000
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 98.975
Ilość akcji: Brak danych
Debiut giełdowy: 1991-06-21
WWW: https://www.idexx.com
CEO: Mr. Jonathan J. Mazelsky
Adres: One IDEXX Drive
Siedziba: 04092 Westbrook
ISIN: US45168D1046
Wskaźniki finansowe
Kapitalizacja (USD) 45 453 653 661
Aktywa: 3 350 766 000
Cena: 565.19
Wskaźnik Altman Z-Score: 16.9
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 52.2
Ilość akcji w obrocie: 99%
Średni wolumen: 573 631
Ilość akcji 80 421 900
Wskaźniki finansowe
Przychody TTM 3 844 817 000
Zobowiązania: 1 732 712 000
Przedział 52 tyg.: 356.14 - 568.474
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: 10.8
P/E branży: Brak danych
Beta: 1.357
Raport okresowy: 2025-08-04
WWW: https://www.idexx.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Sharon E. Underberg Executive Vice President, General Counsel, & Corporate Secretary 881 053 1961
Mr. Jonathan J. Mazelsky President, Chief Executive Officer & Director 2 768 770 1961
Mr. Brian P. McKeon Chief Financial Officer, Executive Vice President & Treasurer 1 395 155 1962
Mr. Michael J. Lane Executive Vice President and GM of Reference Laboratories & Information Technology 1 171 099 1969
Mr. John Hart Senior Vice President of Global Operations 0 0
Mr. Jeffery D. Chadbourne Senior Vice President of Commercial Finance & Sales Operations 0 1976
Dr. Martin Smith Ph.D. Executive Vice President & Chief Technology Officer 0 1969
Mr. Ken Grady Senior Vice President & Chief Information Officer 0 0
Mr. George J. Fennell Senior Vice President & Chief Revenue Officer 0 1969
Mr. Michael P. Johnson Executive Vice President & Chief Human Resources Officer 0 1978
Lista ETF z ekspozycją na akcje IDEXX Laboratories, Inc.
Symbol ETF Ilość akcji Wartość
VOO 2 328 930 1 195 579 504
VO 1 785 272 916 487 233
QQQ 1 652 455 903 909 409
SPY 972 351 532 831 070
VUG 963 752 494 751 726
IVV 958 891 523 132 466
VOT 631 581 324 228 422
XLV 558 639 311 641 370
IWP 521 113 284 298 601
IHI 386 343 210 773 346
IWF 306 246 167 075 452
IWR 282 466 154 102 016
QUAL 281 301 153 874 460
RSP 273 301 149 498 380
VHT 253 413 130 092 097
QQQM 252 251 137 983 819
CSPX.AS 188 441 102 805 606
CSPX.L 188 441 102 805 606
CSSPX.MI 188 441 102 805 606
GSPX.L 188 441 102 805 606
SXR8.DE 188 441 102 805 606
CSP1.L 188 441 102 805 606
EDMU.SW 166 537 90 856 172
EEDG.L 166 537 90 856 172
CBUC.DE 166 537 90 856 172
OM3L.DE 166 537 90 856 172
EEDS.L 166 537 90 856 172
EDMU.DE 166 537 90 856 172
FIW 163 808 89 367 092
SPHQ 154 149 84 321 044
IVE 128 719 70 224 049
SCHG 123 035 67 275 118
IWDG.L 121 214 66 129 679
IWDA.AS 121 214 66 129 679
IWLE.DE 121 214 66 129 679
IWDA.L 121 214 66 129 679
EUNL.DE 121 214 66 129 679
IWDD.AS 121 214 66 129 679
SWDA.MI 121 214 66 129 679
SWDA.L 121 214 66 129 679
SPLG 113 556 61 303 198
VUAA.L 110 929 56 946 511
VUSA.L 110 929 41 898 395
VUAA.MI 110 929 48 501 343
VUSA.AS 110 929 48 501 343
VUSA.MI 110 929 48 501 343
VUSD.L 110 929 56 946 511
VUSA.DE 110 929 48 501 343
VONG 100 494 51 589 599
GSLC 99 056 54 184 622
CNDX.L 96 625 52 714 806
CSNDX.SW 96 625 52 714 806
SXRV.DE 96 625 52 714 806
CNX1.L 96 625 52 714 806
NQSE.DE 96 625 52 714 806
VV 94 446 48 484 798
SPYV 87 359 47 769 550
TQQQ 80 212 43 876 766
SCHX 80 131 43 832 458
IUSV 65 179 35 558 932
ESGU 59 218 32 306 957
IWB 57 837 31 553 724
SPMD.L 45 894 25 037 741
IBCK.DE 45 894 25 037 741
MVUS.L 45 894 25 037 741
IS31.DE 45 894 25 037 741
SPMV.L 45 894 25 037 741
SUSW.L 45 854 25 015 861
SUWS.L 45 854 25 015 861
SGWS.L 45 854 25 015 861
2B7J.DE 45 854 25 015 861
2B7K.DE 45 854 25 015 861
SUWU.SW 45 854 25 015 861
SUWG.L 45 854 25 015 861
SCWS.SW 45 854 25 015 861
IXJ 43 877 23 937 704
IYH 43 491 23 727 105
FLQM 42 435 22 511 767
QYLD 40 981 22 155 967
JQUA 39 371 21 116 242
VWRD.L 38 732 19 883 459
VWRP.L 38 732 14 629 255
VWCE.DE 38 732 16 934 742
VGWL.DE 38 732 16 934 742
VWRL.L 38 732 14 629 255
IMCG 38 605 21 061 526
IUHC.L 37 775 20 608 601
IHCU.L 37 775 20 608 601
QDVG.DE 37 775 20 608 601
IUHE.AS 37 775 20 608 601
QQXT 37 508 20 462 864
SUSA 37 191 20 289 694
QQEW 35 016 19 103 328
FHLC 34 726 18 846 147
EGMW.L 33 103 18 059 535
EEWD.L 33 103 18 059 535
EMND.DE 33 103 18 059 535
EDMW.DE 33 103 18 059 535
EEWG.L 33 103 18 059 535
QLD 30 945 16 927 224
AVUS 30 799 16 847 360
PABU 30 534 16 658 129
NULG 29 835 13 833 296
IUSA.DE 29 622 16 160 316
IUSA.AS 29 622 16 160 316
IUSA.L 29 622 16 160 316
IDUS.L 29 622 16 160 316
SUAP.L 26 412 14 409 337
SUAS.L 26 412 14 409 337
QDVR.DE 26 412 14 409 337
3SUR.DE 26 412 14 409 337
SUUS.L 26 412 14 409 337
SRIL.AS 26 412 14 409 337
36B6.DE 26 412 14 409 337
EXXT.DE 24 450 13 338 838
RSPH 22 934 12 545 127
QQQE 22 481 12 200 663
FXH 22 443 12 244 003
SDUS.L 22 322 12 178 083
SLUS.DE 22 322 12 178 083
SAUA.MI 22 322 12 178 083
SASU.L 22 322 12 178 083
GPSA.L 22 322 12 178 083
SGAS.DE 22 322 12 178 083
ACWI 22 056 12 033 125
IWV 21 663 11 818 698
IUSQ.DE 20 872 11 387 107
SSAC.L 20 872 11 387 107
ISAC.L 20 872 11 387 107
WHCA.AS 19 823 10 814 387
CBUF.DE 19 823 10 814 387
WHCS.AS 19 823 10 814 387
ONEQ 19 439 10 633 327
VOOV 18 971 9 738 952
ISPE.L 17 699 9 655 866
EWSP.L 17 699 9 655 866
ESGV 17 682 7 425 555
I50D.AS 16 378 8 686 891
I500.AS 16 378 8 686 891
I500.L 16 378 8 686 891
SPTM 15 496 8 453 871
IS3Q.DE 15 068 8 220 466
IWFQ.L 15 068 8 220 466
IWQU.L 15 068 8 220 466
FQAL 15 033 8 158 559
IUQD.L 14 129 7 708 464
IUQA.L 14 129 7 708 464
IUQF.L 14 129 7 708 464
QDVB.DE 14 129 7 708 464
XSP.TO 13 610 10 130 008
KNOW 13 117 0
XQQ.TO 12 718 9 466 449
VONE 12 498 6 415 973
QQQI 11 977 6 551 538
PBUS 11 971 6 548 256
FNDX 11 868 6 491 914
PAWZ 11 773 6 439 948
IBCF.DE 11 338 6 185 529
IUSE.L 11 338 6 185 529
ANX.PA 11 221 6 066 521
ANXG.L 11 221 6 066 521
6AQQ.DE 11 221 6 066 521
HNDX.DE 11 221 6 066 521
ANXU.L 11 221 6 066 521
QGRW 11 215 5 862 080
UMDV.AS 11 124 6 069 075
IVV.AX 11 120 9 312 708
XUS.TO 10 308 7 672 456
AVLV 10 119 5 535 194
OMFL 9 936 5 435 091
IXJ.AX 9 882 8 275 630
LSPU.L 9 605 5 192 847
ETFSP500.WA 9 605 5 192 847
SP5H.PA 9 605 5 192 847
SP5L.L 9 605 5 192 847
LSPX.L 9 605 5 192 847
LYP2.DE 9 605 5 192 847
6TVM.DE 9 605 5 192 847
VHVE.L 8 675 4 453 398
VEVE.L 8 675 3 276 587
VGVF.DE 8 675 3 792 959
VGVE.DE 8 675 3 792 959
VDEV.L 8 675 4 453 398
IMCB 7 718 4 210 882
SSO 7 639 4 178 609
ILCG 7 635 4 165 481
BIBL 7 614 4 164 934
BBUS 7 472 4 007 532
USCA 6 720 3 675 907
SAWD.L 6 675 3 641 445
S6DW.DE 6 675 3 641 445
SDWD.L 6 675 3 641 445
SNAW.DE 6 675 3 641 445
VTHR 6 275 3 221 334
VNRG.L 6 186 2 336 480
VNRA.L 6 186 3 175 644
VNRA.DE 6 186 2 704 696
VNRT.DE 6 186 2 704 696
VNRT.L 6 186 2 336 480
VDNR.L 6 186 3 175 644
SCHK 6 057 3 248 611
SPXL 5 993 3 252 461
PTNQ 5 957 3 258 538
L100.L 5 853 3 164 365
XHE 5 802 3 276 908
URTH 5 546 3 025 512
USCL 5 362 2 925 292
QFLR 5 268 2 881 648
EUSA 5 190 2 831 323
PTLC 5 152 2 818 195
CSH2.PA 5 022 2 715 094
GPIQ 4 970 2 718 639
XYLD 4 903 2 650 757
GSEW 4 758 2 602 673
USXF 4 709 2 569 305
AVMV 4 476 2 448 416
UPGD 4 169 2 280 484
GSID 4 030 2 204 450
GSUS 4 030 2 204 450
XHC.TO 4 006 2 981 568
CATH 3 777 2 041 997
VFQY 3 750 1 574 812
XUU.TO 3 701 2 740 308
UPRO 3 680 2 012 996
QUS 3 664 1 997 826
XEQT.TO 3 544 2 638 027
IYY 3 459 1 887 184
SPYX 3 456 1 878 956
PRF 3 373 1 845 064
CSUS.SW 3 215 1 753 714
CSUS.L 3 215 1 753 714
SXR4.DE 3 215 1 753 714
CU1.L 3 215 1 753 714
SPUS 3 199 1 749 884
GUSA 2 715 1 485 132
SUSL 2 681 1 466 533
IHVV.AX 2 668 2 233 975
LSAF 2 539 1 388 858
QVML 2 411 1 318 841
RWL 2 380 1 301 883
FINW.L 2 242 1 212 114
LYPD.DE 2 242 1 212 114
JHML 2 241 1 141 856
CFA 2 191 1 198 498
TMFC 2 189 0
HLAL 2 121 871 221
PTL 2 097 1 147 079
XAW.TO 1 967 1 464 243
QDVC.DE 1 955 1 066 669
IUSZ.L 1 955 1 066 669
IUSF.L 1 955 1 066 669
FLSP 1 931 1 024 395
TOLL 1 913 1 046 430
IDNA.L 1 900 1 036 583
IQQN.DE 1 900 1 036 583
INAA.L 1 900 1 036 583
INAA.SW 1 900 1 036 583
USPX 1 896 1 005 828
NUSI 1 812 784 596
CFO 1 730 946 327
IWLD.AX 1 722 1 442 097
AVLC 1 712 936 481
TILT 1 705 921 791
XSUS.TO 1 701 1 266 113
CURE 1 686 915 009
USSG 1 646 900 378
CRBN 1 633 891 079
GPIX 1 617 884 515
ILCB 1 554 847 865
IGUS.L 1 529 834 398
MODL 1 521 832 002
IWDC.SW 1 501 819 108
QLC 1 500 810 960
IWQE.MI 1 427 778 395
QDPL 1 402 766 908
AVSU 1 386 758 155
STRV 1 323 723 694
ISPY 1 301 711 660
NTSX 1 239 647 625
V3AA.L 1 193 612 438
V3AL.L 1 193 612 438
SIZE 1 181 644 377
CDX 1 173 636 660
SPYI 1 148 627 967
IQSU 1 102 602 805
R1GR.L 1 091 595 205
ETHO 1 088 595 146
EQAL 1 086 594 052
IHWL.AX 1 074 899 426
IUSC.SW 1 064 580 364
USNZ 1 047 572 719
RSPA 1 027 561 779
QQA 1 019 557 403
XWD.TO 988 728 556
GGUS 962 526 223
XUSR.TO 923 687 021
IQQQ 913 499 420
QIS 908 492 705
RXL 862 471 522
EPS 847 442 726
WPAB.AS 846 461 676
WPAB.SW 846 461 676
WPAD.AS 846 461 676
SHE 830 451 710
KOKU 787 430 496
IWFS.L 753 410 804
IS3T.DE 753 410 804
IWSZ.L 753 410 804
XQLT.TO 726 540 389
XVV 704 385 095
OALC 692 378 530
AVMC 690 377 436
HCMT 586 318 028
FNDB 549 294 450
QQMG 531 290 462
XUH.TO 529 288 429
BLES 529 289 368
QYLG 500 270 320
CRTC 496 271 316
SPXT 474 259 282
SAWI.AS 424 231 385
CBUY.DE 424 231 385
HQGO 401 217 626
IUS 393 214 974
IGWD.L 383 208 900
AFLG 363 198 038
NBDS 327 0
DEUS 317 173 402
DUBS 304 166 291
QNXT 296 157 270
SZNE 276 150 974
STXG 274 149 880
QWLD 262 143 086
TOK 257 140 034
SPUU 252 136 762
VLU 248 135 770
LSEQ 240 130 250
NZAC 237 129 362
ESG 231 124 887
PBP 228 124 718
QQQG 221 117 421
EGUS 218 119 248
GEQT.TO 201 149 271
MFUS 198 106 195
GLOF 197 107 475
ONOF 191 103 262
ONEO 182 99 136
IQM 178 94 429
GGRO.TO 177 131 870
ESGG 140 75 689
TGRW 135 69 303
GBAL.TO 117 86 948
SPXN 115 62 906
QARP 114 62 359
SPMV 112 61 265
SPXE 106 57 983
NVIR 105 57 436
SPGM 100 54 627
PHDG 94 51 418
QRMI 93 50 279
XYLG 85 45 954
IUME.AS 81 44 307
XMAG 77 42 119
XRMI 75 40 548
NULC 51 23 646
SQEW 46 25 162
QHDG 45 24 615
MMTM 31 16 887
NTSX.MI 30 15 915
NTSX.L 30 15 915
WDMF.AX 27 22 611
GCNS.TO 25 18 383
INRO 24 12 751
XTR.TO 22 11 806
JCTR 18 9 654
QTR 13 7 028
QCLR 12 6 487
NZUS 8 4 379
XCLR 5 2 703
XTR 3 1 621
SPXS.L 0 0
EQL.TO 0 0
QQC.TO 0 0
QQC-F.TO 0 0
PXS.TO 0 0
Wiadomości dla IDEXX Laboratories, Inc.
Tytuł Treść Źródło Aktualizacja Link
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. zacks.com 2025-05-15 13:11:13 Czytaj oryginał (ang.)
IDEXX Laboratories: Growth Remains Despite Weak Clinical Visits IDEXX Laboratories, Inc. delivered strong Q1 FY25 results with 4.7% organic revenue and 7% adjusted EPS growth, despite weak US clinical visits. I see catalysts ahead: potential U.S. tax cuts, normalization of consumer spending, and robust pricing power supporting profit growth. Management guides for 6%-9% organic revenue and 8%-12% adjusted EPS growth in FY25; I model 8.2% revenue growth and margin expansion. seekingalpha.com 2025-05-14 18:35:10 Czytaj oryginał (ang.)
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year? Here is how Idexx Laboratories (IDXX) and AngioDynamics (ANGO) have performed compared to their sector so far this year. zacks.com 2025-05-14 14:41:31 Czytaj oryginał (ang.)
IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Andrew Emerson, Executive Vice President and Chief Financial Officer, and Tina Hunt, Executive Vice President, Global Strategy and Commercial, will participate in a fireside chat at the Stifel Jaws & Paws Conference on Wednesday, May 28, 2025 from 10:55 am – 11:25 am (EDT). A live audio webcast of the presentation will be available through a link on. businesswire.com 2025-05-13 18:30:00 Czytaj oryginał (ang.)
Compared to Estimates, Idexx (IDXX) Q1 Earnings: A Look at Key Metrics Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-05-01 14:36:17 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q1 2025 Earnings Conference Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Emerson - EVP, CFO and Treasurer Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Erin Wright - Morgan Stanley Jon Block - Stifel Brandon Vazquez - William Blair Dan Clark - Leerink Partners David Westenberg - Piper Sandler Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' First Quarter 2025 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2025-05-01 14:35:25 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Beats Q1 Earnings Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.96 per share, beating the Zacks Consensus Estimate of $2.92 per share. This compares to earnings of $2.81 per share a year ago. zacks.com 2025-05-01 12:40:23 Czytaj oryginał (ang.)
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics Animal diagnostics maker IDEXX Laboratories on Thursday raised its annual profit forecast after it beat Wall Street estimates for quarterly profit, as it benefited from customer retention and increased demand for its tests and equipment. reuters.com 2025-05-01 12:21:46 Czytaj oryginał (ang.)
IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. “IDEXX drove solid execution in the first quarter while advancing key enablers of our innovation-driven growth strategy. At the end of March, IDEXX launched a first-of-its-kind innovation, IDEXX Cancer Dx™, in our North American reference laboratories,” said Jay Mazelsky, President and Chief Executive Officer. “Customers have been askin. businesswire.com 2025-05-01 10:30:00 Czytaj oryginał (ang.)
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss? The first-quarter 2025 earnings season is underway, with a number of top MedTech companies already releasing their numbers. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar. zacks.com 2025-04-30 14:35:40 Czytaj oryginał (ang.)
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-29 14:50:57 Czytaj oryginał (ang.)
Seeking Clues to Idexx (IDXX) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics Besides Wall Street's top -and-bottom-line estimates for Idexx (IDXX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025. zacks.com 2025-04-29 14:21:11 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-24 15:08:53 Czytaj oryginał (ang.)
IDXX Gears Up for Q1 Earnings: What to Expect From the Stock? IDEXX Laboratories' first-quarter 2025 performance is expected to have benefited from a strong execution against strategic priorities. zacks.com 2025-04-21 13:35:41 Czytaj oryginał (ang.)
IDEXX (IDXX) Surges 10.0%: Is This an Indication of Further Gains? IDEXX (IDXX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. zacks.com 2025-04-10 10:50:37 Czytaj oryginał (ang.)
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-04-09 14:45:33 Czytaj oryginał (ang.)
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report? Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-04 17:15:45 Czytaj oryginał (ang.)
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP. zacks.com 2025-04-04 13:55:40 Czytaj oryginał (ang.)
IDEXX Laboratories to Release 2025 First Quarter Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2025 first quarter financial results for Thursday, May 1, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2025 Earnings Snapshot through a link on the IDEXX website,. businesswire.com 2025-04-03 17:30:00 Czytaj oryginał (ang.)
Why Investors Need to Take Advantage of These 2 Medical Stocks Now Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP. zacks.com 2025-04-02 13:55:56 Czytaj oryginał (ang.)
Should You Hold IDEXX Stock in Your Portfolio for Now? IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising. zacks.com 2025-02-18 10:50:25 Czytaj oryginał (ang.)
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March. businesswire.com 2025-02-13 16:00:00 Czytaj oryginał (ang.)
IDEXX Laboratories And Its Real Value IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years. seekingalpha.com 2025-02-10 13:27:02 Czytaj oryginał (ang.)
Why Idexx Labs Stock Rocketed Higher This Week Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence. fool.com 2025-02-07 09:09:14 Czytaj oryginał (ang.)
IDEXX Laboratories: I See Pet Healthcare As An Interesting Market For The Future IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage. seekingalpha.com 2025-02-06 16:31:03 Czytaj oryginał (ang.)
Idexx Stock, AbbVie, and Molina Buck Downward Tariff Trend. These Are Today's Top S&P 500 Performers. Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street. barrons.com 2025-02-03 13:31:00 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q4 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2025-02-03 13:26:14 Czytaj oryginał (ang.)
IDEXX Laboratories Stock Jumps on Testing Products Demand, Higher Prices Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices. investopedia.com 2025-02-03 13:22:29 Czytaj oryginał (ang.)
Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2025-02-03 12:30:42 Czytaj oryginał (ang.)
Idexx: Q4 EPS, Revenue Beat Forecast Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million. fool.com 2025-02-03 11:06:09 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $2.40 per share. This compares to earnings of $2.32 per share a year ago. zacks.com 2025-02-03 10:41:23 Czytaj oryginał (ang.)
Animal diagnostics maker IDEXX beats quarterly estimates despite low vet visits IDEXX Laboratories beat Wall Street estimates for fourth-quarter revenue and profit on Monday, helped by strong demand for its veterinary diagnostic services despite persistent weakness in visits to the vet clinic. reuters.com 2025-02-03 09:57:11 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results. “IDEXX had a solid finish to 2024, supported by continued high levels of execution by IDEXX teams globally,” said Jay Mazelsky, President and Chief Executive Officer. "The Company is on the front end of a new wave of major innovation. In Q4, we began shipping the IDEXX inVue Dx™ Cellular Analyzer, our transformational sli. businesswire.com 2025-02-03 08:30:00 Czytaj oryginał (ang.)
IDXX Gears Up for Q4 Earnings: What to Expect From the Stock? IDEXX Laboratories' fourth-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities. zacks.com 2025-01-27 12:11:14 Czytaj oryginał (ang.)
IDXX Stock Set to Benefit From IDEXX Cancer Dx Diagnostic Panel Launch IDEXX launches new cancer Dx Panel with early detection test for canine lymphoma. zacks.com 2025-01-24 11:01:16 Czytaj oryginał (ang.)
IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2024 fourth quarter and full year financial results for Monday, February 3, 2025, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q4 2024 Earnings Snapshot through a link on. businesswire.com 2025-01-16 18:15:00 Czytaj oryginał (ang.)
IDEXX Stock Suffers Due to Macroeconomic Issues and FX Woes With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check. zacks.com 2025-01-15 12:41:32 Czytaj oryginał (ang.)
Why Idexx Laboratories (IDXX) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-26 12:46:11 Czytaj oryginał (ang.)
SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX Sustainability Roundtable Inc. announced Synopsys, IDEXX, and Juniper Networks as winners of the 2024 SBER Awards for standout leadership in sustainability globenewswire.com 2024-12-19 12:09:00 Czytaj oryginał (ang.)
A Once-in-a-Decade Opportunity: 2 Magnificent S&P 500 Stocks Down 37% and 28% to Buy Before 2025 One of my favorite ways to add money to my portfolio is to invest in proven compounders with track records of delivering market-beating results after short-term pullbacks. This idea is especially true when the stocks in question are trading at what could prove to be once-in-a-decade opportunities. fool.com 2024-12-13 10:45:00 Czytaj oryginał (ang.)
Global Expansion to Support IDEXX Stock Despite Macroeconomic Issues IDEXX focuses on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. zacks.com 2024-12-11 14:01:21 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company's Board of Directors authorized an increase in its ongoing share repurchase program, authorizing the repurchase of up to five million additional shares of the Company's common stock. Repurchases may be made at management's discretion from time to time in the open market (including through Rule 10b5-1 plans) or in negotiated transactions. Thes. businesswire.com 2024-12-09 09:30:00 Czytaj oryginał (ang.)
Should You Hold IDEXX Stock in Your Portfolio for Now? IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising. zacks.com 2024-11-22 13:15:19 Czytaj oryginał (ang.)
IDEXX Announces CFO Transition WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance, will succeed Mr. McKeon as IDEXX's Executive Vice President, Chief Financial Officer and Treasurer, effective March 1, 2025. Mr. McKeon will serve as EVP and Special Advisor to the Co. businesswire.com 2024-11-21 09:30:00 Czytaj oryginał (ang.)
IDEXX Laboratories Q3: Weak End-Market Demand Continues I reiterate a 'Sell' rating on IDEXX due to weak U.S. clinical visits and demand, with a one-year price target of $400 per share. IDEXX's Q3 results showed a 2.1% decline in same-store clinical visits and missed market expectations, leading to lowered revenue growth guidance for FY24. Despite strong recurring revenue growth and high retention rates, ongoing macroeconomic challenges and high-interest rates are expected to impact IDEXX's business growth. seekingalpha.com 2024-11-10 21:50:02 Czytaj oryginał (ang.)
Is It Time to Buy October's Worst-Performing Nasdaq Stocks? Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. fool.com 2024-11-06 06:11:00 Czytaj oryginał (ang.)
A Once-in-a-Decade Opportunity: 1 Super S&P 500 Stock Down 40% to Buy After Its Recent Pullback Trading at its most reasonable valuation since 2016, this pet healthcare diagnostics leader could be a once-in-a-decade opportunity today. fool.com 2024-11-05 11:53:00 Czytaj oryginał (ang.)
IDEXX Laboratories, Inc. (IDXX) Q3 2024 Earnings Call Transcript IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Brian McKeon - CFO Jay Mazelsky - President and CEO Conference Call Participants Michael Ryskin - Bank of America Jonathan Block - Stifel Erin Wright - Morgan Stanley Brandon Vasquez - William Blair David Westenberg - Piper Sandler Operator Good morning, and welcome to the IDEXX Laboratories Third Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded. seekingalpha.com 2024-10-31 15:59:07 Czytaj oryginał (ang.)
CORRECTING and REPLACING IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--In the 2024 Growth and Financial Performance Outlook section, second paragraph, second sentence should read: At midpoint, projected full year comparable operating profit margin expansion of 30 - 60 basis points includes a ~40 basis point negative growth impact from lapping a customer contract resolution payment in the first quarter of 2023. (instead of: At midpoint, projected full year comparable operating profit margin expansion of 70 - 100 basis points inclu. businesswire.com 2024-10-31 15:15:00 Czytaj oryginał (ang.)
Idexx Laboratories Adjusts Guidance As Q3 Revenue Growth Slows, Analyst Notes Fewer Veterinary Visits, Looks Towards Long-Term Growth Idexx Laboratories Inc IDXX reported third-quarter adjusted EPS of $2.79, up 12% year-over-year, beating the consensus of $2.68. benzinga.com 2024-10-31 14:55:09 Czytaj oryginał (ang.)
IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments. zacks.com 2024-10-31 14:10:27 Czytaj oryginał (ang.)
Idexx (IDXX) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com 2024-10-31 12:36:22 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Q3 Earnings Surpass Estimates Idexx Laboratories (IDXX) came out with quarterly earnings of $2.80 per share, beating the Zacks Consensus Estimate of $2.69 per share. This compares to earnings of $2.53 per share a year ago. zacks.com 2024-10-31 10:40:21 Czytaj oryginał (ang.)
IDEXX laboratories cuts annual revenue forecast for third time as pet clinic visits slow IDEXX Laboratories trimmed its annual revenue forecast for the third time on Thursday, as the animal health diagnostic equipment maker sees fewer visits to veterinary clinics from pet owners. reuters.com 2024-10-31 10:01:34 Czytaj oryginał (ang.)
IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company reports revenues of $976 million for the third quarter of 2024, an increase of 7% as reported and 6% organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and 6% organic, and Water revenue growth of 13% as reported and organic. CAG Diagnostics recurring revenue growth of 7% as repor. businesswire.com 2024-10-31 08:30:00 Czytaj oryginał (ang.)
Seeking Clues to Idexx (IDXX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics Evaluate the expected performance of Idexx (IDXX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com 2024-10-28 12:21:45 Czytaj oryginał (ang.)
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy? Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-10-24 15:05:37 Czytaj oryginał (ang.)